Bioventus (BVS) Revenue (2020 - 2026)

Bioventus' Revenue history runs 7 years deep, the most recent figure standing at $132.1 million for Q1 2026.

• Quarterly Revenue rose 6.63% year-over-year to $132.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $576.3 million (up 1.52% YoY) and the FY2025 annual result came in at $568.1 million, down 0.91% from the prior year.
• Revenue was $132.1 million for Q1 2026 at Bioventus, down from $157.9 million in the prior quarter.
• Across five years, Revenue topped out at $157.9 million in Q4 2025 and bottomed at $117.3 million in Q2 2022.
• A 5-year average of $135.2 million and a median of $135.4 million in 2023 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue jumped 43.42% — and 2023, when it dropped 6.12%.
• Bioventus' Revenue stood at $125.8 million in 2022, then grew by 7.62% to $135.4 million in 2023, then climbed by 13.45% to $153.6 million in 2024, then climbed by 2.77% to $157.9 million in 2025, then declined by 16.35% to $132.1 million in 2026.
• Business Quant data shows BVS's Revenue at $132.1 million in Q1 2026, $157.9 million in Q4 2025, and $138.7 million in Q3 2025.